



## Application of Ene-Like Reactions of Aldehydes with Vinyl Ethers: Facile Assembly of Benzazocenone Intermediates for Mitomycinoids


Marco A. Ciufolini,\*<sup>1</sup> Mingying Chen, Dennis P. Lovett and Melissa V. Deaton

Department of Chemistry, MS 60, Rice University, 6100 Main St., Houston, Texas 77005-1892, U.S.A.

**ABSTRACT:** Benzazocenone intermediates for mitomycinoids are now available in only six steps. Key phases of this sequence include the ene-like reaction of 2-methoxypropene with a 2-azidophenylacetaldehyde and a novel heterocyclic ring formation/expansion reaction. © 1997 Elsevier Science Ltd.


Mitomycinoids, e.g., mitomycin C, **1**, and FR900482, **2**, are potent antitumor agents that have elicited much attention from the synthetic community.<sup>2</sup> These molecules could be constructed starting from a benzazocenone of the type **3** (Scheme 1), and indeed, some especially successful syntheses of mitomycinoids proceed through similar 8-membered ring intermediates.<sup>3</sup> However, benzazocenones and related medium ring compounds are generally difficult to assemble. Recent progress in olefin metathesis chemistry has facilitated this task significantly.<sup>4</sup> In this Letter, we propose a practical alternative that relies on our ene-like reaction of ordinary

Scheme 1




aldehydes with those vinyl ethers such as 2-methoxypropene (MP), that display the oxygen atom at the central carbon of an allylic system.<sup>5</sup> This process,<sup>6</sup> outlined in Scheme 2, is efficient and economical; it requires only 0.5 mol% or less of a catalyst consisting of the 1:1 complex of Yb(fod)<sub>3</sub> and acetic acid, it occurs at room temperature it requires no drastic measures to exclude air or moisture, it affords end-products in nearly quantitative yield and in high purity, and it offers much strategic and tactical opportunity.<sup>7</sup>

Scheme 2



Central to the success of our plan was the ability of 1,3-dipolar functionality, e.g., an azide strategically placed within the substrate aldehyde, to intercept the vinyl ether subunit of the ene product as a prelude to a novel photochemical ring expansion. This is shown in Scheme 3. Ene-like reaction of 2-(2-azidophenyl)-acetaldehyde **4**<sup>8</sup> with MP furnished ene adduct **5** (MIP = 2-methoxyisopropyl; cf. Scheme 2), cyclization of which to triazoline **6** was best effected in refluxing toluene (55% chromat. yield from **4**). Irradiation of a solution of **6** in moist THF with UV light from a sunlamp (pyrex flask), and without the need for a sensitizer, promoted efficient conversion to benzazocenone **9** in 84% chromatographed yield. Only three steps are thus necessary to assemble **9** from readily available materials, thanks to synergy between our ene-like reaction and the photochemistry of Scheme 3.


### Scheme 3




(a) MP (20 equiv.),  $\text{CH}_2\text{Cl}_2$ , 0.5 mol% of 1:1  $\text{Yb}(\text{fod})_3\text{-AcOH}$ , RT, 20 h; (b) Toluene, reflux, cat.  $\text{K}_2\text{CO}_3$ , 14 h, 55% chrom. a-b; (c) hv (Sylvania 275 W sunlamp), cat.  $\text{K}_2\text{CO}_3$ , moist THF, 32 h, 78 - 84%.

Various aspects of Scheme 3 deserve further comment. First, compound **6** emerged as a 7:1 mixture of isomers. The major one, m.p. 88-90° C (recr'd. EtOAc/hexanes), is believed to be the *anti* diastereomer (shown above), due to large couplings (11 and 8 Hz) between the H on the OMIP-bearing C atom and two neighboring H's. Scheme 4 shows the 7-membered ring portion of the MM+ optimized structures of the *anti* and *syn* diastereomers of **10**, an analog of **6** wherein the MIP unit is approximated by a computationally more tractable methyl group (the rest of the molecules is invisible for clarity). Only the *anti* isomer displays sufficiently large dihedral angles between proton **a** and neighboring hydrogens **b** and **e** to permit 8-11 Hz couplings. Moreover, approximate transition states (TS) for the dipolar cycloaddition leading to the isomeric triazolines were estimated by fixing the distance between the terminal N atoms of the azide and the olefinic C atoms of the vinyl ether to 2.4 Å. It appears that the approximate TS leading to the *syn* isomer is affected by a severe nonbonding interaction between the oxygen atoms on the vinyl ether and the OMe / OMIP unit. This interaction is absent in the TS

### Scheme 4



Scheme 5




(a) cat.  $\text{H}^+$ ; (b)  $h\nu$  (sunlamp), cat.  $\text{K}_2\text{CO}_3$ , PhH, MeOH; (c) MP,  $\text{CH}_2\text{Cl}_2$ , 0.005 equiv. 1:1  $\text{Yb}(\text{fod})_3$  : AcOH, r.t., 95%; (d) cf. Scheme 3; 86% overall.

leading to the *anti* isomer, which therefore should form preferentially.<sup>9</sup> Second, the triazoline was prone to undergo loss of MeOH with consequent aromatization to triazole 11 (Scheme 5). This triazole resisted photochemical deazonation, but fortunately aromatization of 6 was easily suppressed by handling it always in the presence of some solid  $\text{K}_2\text{CO}_3$ . Third, conversion of 6 to 9 probably starts with deazonation (cf. Scheme 3). The resulting 1,3-diradical 7 would be expected to cyclize to methoxyaziridine 8. Rapid hydrolysis of this fragile, strained material would ensue in the presence of water. In support of this mechanistic picture, irradiation of 6 in Ph / MeOH led to acetal 12, in addition to 9, presumably through capture of 8 by MeOH. Fourth, the ene step is not particularly sensitive to additional substituents *ortho* to the reaction site. This is underscored by the successful formation of adduct 14 from aldehyde 13, which displays a substitution pattern more closely resembling 2. Finally, the tandem dipolar cycloaddition-photochemical ring expansion of Scheme 3 succeeds also with other substrates. To illustrate, 2-azidobenzaldehyde, 15,<sup>8b</sup> was readily advanced to benzazepinone 16.

Experiments directed toward the conversion of 9 to an azocenone of the type 3 revealed an interesting property of the final heterocycle. Briefly,  $\text{NaBH}_4$  reduction of 9, acetylation of the mixture of diastereomers of 17 and catalytic TPAP oxidation<sup>10</sup> of the free carbinol in 18 (the MIP group was cleaved during acidic workup of

Scheme 6



(a)  $\text{NaBH}_4$ , EtOH,  $-20^\circ\text{C}$ ; (b)  $\text{Ac}_2\text{O}$ , pyr, acid workup ( $-\text{MIP}$ ), 65% a-b; (c) cat. TPAP, NMO,  $\text{CH}_2\text{Cl}_2$ ; (d) DBU, 78% chrom.; (e)  $\text{H}_3\text{O}^+$ .

the acetylation reaction) produced acetoxyketone **19** (Scheme 6). This material was rather resistant to  $\beta$ -elimination to **20**. Elimination could be forced by exposure of **19** to DBU at room temperature; however, rapid deconjugation of the presumed enone intermediate **20** occurred under these conditions, resulting in the ultimate formation of enamide **21**. The structure of **21** rests on extensive 2D HMBC studies<sup>11</sup> and on its chemical conversion into indole **22**. It seems likely that a similar elimination reaction should produce the desired regiochemical outcome if the ketone in **19** were not expressed,<sup>12</sup> since this would deny the intermediate olefin a pathway for rearrangement. We hope to parlay the favorable premises detailed in this paper into a synthesis of at least some mitomycinoids. Developments in this area will be reported in due course.<sup>13</sup>

**Acknowledgment.** We thank NIH (CA-55268), NSF (CHE 95-26183), the Robert A. Welch Foundation (C-1007), and the Alfred P. Sloan Foundation, for support of our research.

### References and Footnotes

1. Fellow of the Alfred P. Sloan Foundation.
2. Reviews: (a) Kishi, Y. *J. Nat. Prod.* **1979**, *42*, 549; (b) Remers, W. A.; Dorr, R. T., in: *Alkaloids: Chemical and Biological Perspectives*; Pelletier, S. W., Ed.; John Wiley & Sons: New York, NY, 1988; vol. 6, ch. 1. Recent syntheses: (c) Fukuyama, T.; Yang, L. *J. Am. Chem. Soc.* **1987**, *109*, 7881; (d) Schkeryantz, J. M.; Danishefsky, S. J. *J. Am. Chem. Soc.* **1995**, *117*, 4722.
3. Ref. 2a-b as well as: (a) Fukuyama, T.; Xu, L. *J. Am. Chem. Soc.* **1992**, *114*, 383; (b) Katoh, T.; Itoh, E.; Yoshino, T.; Terashima, S. *Tetrahedron Lett.* **1996**, *37*, 3471; (c) Yoshino, T.; Nagata, Y.; Itoh, E.; Hashimoto, M.; Katoh, T.; Terashima, S. *Tetrahedron Lett.* **1996**, *37*, 3475; (d) Katoh, T.; Yoshino, T.; Nagata, Y.; Nakatani, S.; Terashima, S. *Tetrahedron Lett.* **1996**, *37*, 3479.
4. (a) Martin, S. F.; Wagman, A. S. *Tetrahedron Lett.* **1995**, *36*, 1169; (b) Martin, S. F.; Chen, H. J.; Courtney, A. K.; Liao, Y. S.; Patzel, M.; Ramser, M. N.; Wagman, A. S. *Tetrahedron* **1996**, *52*, 7251.
5. Deaton, M. V.; Ciufolini, M. A. *Tetrahedron Lett.* **1993**, *34*, 2409.
6. Ciufolini, M. A., in: *Advances in Heterocyclic Natural Product Synthesis*; Pearson, W. H., Ed.; JAI Press: Greenwich, CT, 1996, vol. 3, ch. 1.
7. Ciufolini, M. A.; Deaton, M. V.; Zhu, S.; Chen, M. *Tetrahedron* **1997**, *53*, *In Press*.
8. a. Made from 2-(2-aminophenyl)-ethanol (Aldrich) by (i) diazotization/azidation; (ii) PCC oxidation ( $\approx 40\%$ ). Cf.: b. Ardakani, M. A.; Smalley, R. K.; Smith, R. H. *J. Chem. Soc., Perkin Trans. I* **1986**, 4139.
9. All calculations (MM+ force field) were carried out with the Hyperchem 4.0<sup>®</sup> package, by Hypercube, Inc..
10. Ley, S. V.; Norman, J.; Griffith, W. P.; Marsden, S. P. *Synthesis* **1994**, 639.
11. We thank Drs. Lawrence Alemany and William Wilson for invaluable assistance with these measurements.
12. Related eliminations tend to occur away from heteroatoms, e.g.: Danishefsky, S.; Berman, E. M.; Ciufolini, M.; Etheredge, S. J.; Segmuller, B. E. *J. Am. Chem. Soc.* **1985**, *107*, 3891.
13. All compounds were fully characterized (<sup>1</sup>H, <sup>13</sup>C NMR; IR; low, high resolution MS). <sup>1</sup>H NMR data for representative compounds: **6** <sup>1</sup>H (C<sub>6</sub>D<sub>6</sub>) 7.82 (d, 1H, J = 7.8), 7.08-6.74 (m, 3H), 4.31 (dddd, 1H, J = 11.0, 7.7, 4.7, 3.4), 4.14 (d, 1H, J = 18.4), 3.48 (d, 1H, J = 18.4 Hz), 3.10 (s, 3H), 2.96 (m, 2H), 2.57 (dd, 1H, J = 13.3, 2.2), 2.46 (s, 3H), 1.60 (dd, 1H, J = 11.0, 2.0), 1.53 (dd, 1H, J = 13.3, 11.0), 1.28 (s, 3H), 1.27 (s, 3H). **9** <sup>1</sup>H (C<sub>6</sub>D<sub>6</sub>) 6.99 (t, 1H, J = 7.3), 6.94 (d, 1H, J = 7.9), 6.73 (t, 1H, 7.), 6.26 (d, 1H, J = 7.9), 4.13 (m, 1H), 3.43 (d, 1H, J = 18), 3.23 (d, 1H, J = 18.0), 3.12 (s, 3H), 3.01 (dd, 2H, J = 10.3, 4.2), 2.81 (dd, 2H, J = 4.2, 3.6), 1.23 (s, 6H). **21**: <sup>1</sup>H (CDCl<sub>3</sub>) 7.45-7.20 (m, 5H), 5.02 (dt, 1H, J = 9.6, 5.3), 3.81 (d, 1H, J = 16.7), 3.58 (d, 1H, J = 16.7), 2.82 (dt, 1H, J = 13.8, 3.5), 2.55 (dd, 1H, J = 13.8, 9.8), 1.80 (s, 3H).

(Received in USA 15 April 1997; revised 7 May 1997; accepted 8 May 1997)